Introduction {#tca12304-sec-0005}
============

Inflammation and cancer are related diseases; inflammation can not only promote carcinogenesis but tumor cells can also stimulate systemic inflammation, which is reflected in changes in various inflammatory markers.[1](#tca12304-bib-0001){ref-type="ref"}, [2](#tca12304-bib-0002){ref-type="ref"} However, most inflammatory markers are not routinely assessed before cancer treatments.[3](#tca12304-bib-0003){ref-type="ref"}, [4](#tca12304-bib-0004){ref-type="ref"}, [5](#tca12304-bib-0005){ref-type="ref"}

For clinical use, prognostic factors should be simple, inexpensive, and reproducible.[5](#tca12304-bib-0005){ref-type="ref"} One attractive marker of cancer‐related inflammation is the neutrophil‐lymphocyte ratio (NLR), which is readily available in complete blood cell (CBC) counts and is associated with disease prognosis in various types of cancer.[6](#tca12304-bib-0006){ref-type="ref"}, [7](#tca12304-bib-0007){ref-type="ref"}, [8](#tca12304-bib-0008){ref-type="ref"}

However, the utility of this marker in epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) is not known. Recent discovery of EGFR mutation and use of tyrosine kinase inhibitors (TKIs) has substantially improved survival outcome.[9](#tca12304-bib-0009){ref-type="ref"}, [10](#tca12304-bib-0010){ref-type="ref"} However, it is not known whether the NLR can reflect disease prognosis. Herein, we investigated whether the NLR is a prognostic factor of progression‐free survival (PFS) in EGFR‐mutant NSCLC patients treated with first‐line cytotoxic chemotherapy or TKI.

Methods {#tca12304-sec-0006}
=======

Patients and study design {#tca12304-sec-0007}
-------------------------

We retrospectively analyzed the EGFR‐TKI registry database of the Seoul National University Hospital (Seoul, Korea). Patients who met the following inclusion criteria were enrolled in the study: (i) pathological diagnosis of NSCLC between January 2005 and December 2011; (ii) presence of a gefitinib‐sensitive EGFR mutation, specifically, either an in‐frame deletion in exon 19 (del19) or an L858R point mutation in exon 21; (iii) clinical stage IIIB or IV disease, as determined by imaging; and (iv) a CBC count within 31 days of commencing first‐line treatment. The exclusion criteria were: presence of an active infection, or treatment with steroids or antimicrobial drugs before the CBC count was performed. Objective tumor responses to chemotherapy were assessed by Response Evaluation Criteria in Solid Tumors (version 1.0).[11](#tca12304-bib-0011){ref-type="ref"}

This study was approved by the institutional review board of the Seoul National University Hospital and was performed in accordance with the Declaration of Helsinki.

Statistical analyses {#tca12304-sec-0008}
--------------------

Categorical variables were analyzed using Pearson\'s χ2 or Fisher\'s exact tests. Survival analyses were performed using the Kaplan--Meier method or Cox proportional hazard model. All groups were compared with the log‐rank test. Receiver operating characteristic curve analysis was performed to determine the NLR cut‐off, which produced the best sensitivity and specificity for median PFS. Specifically, NLRs \>3.0 were considered to be high, while those ≤3.0 were considered to be low.

Univariate and multivariate analyses were performed using the Kaplan--Meier method and Cox regression. A two‐sided *P* value \<0.05 was considered statistically significant.

Results {#tca12304-sec-0009}
=======

Patients {#tca12304-sec-0010}
--------

We identified 270 patients in the NSCLC database who had EGFR mutations and received TKIs. Of these, 20 were excluded (7 received steroids or antimicrobials before treatment and 13 did not have a CBC count within 31 days of the first treatment), which left 250 patients in the study (Fig [1](#tca12304-fig-0001){ref-type="fig"}). Patients\' median age was 64 years (range: 31--85). Most patients had lung adenocarcinoma tumors (91.6%). Eastern Cooperative Oncology Group performance status (PS) was 0 or 1 in 214 patients (85.6%) and ≥2 in 36 patients (1.4%). First‐line treatment was cytotoxic chemotherapy in 165 patients (66%) and TKIs in 85 patients (34%). In the first‐line cytotoxic chemotherapy group, 155 out of 165 patients (93.9%) received EGFR‐TKI treatment as second‐line treatment, while the remaining patients received EGFR‐TKI as third‐line or further. In the first‐line EGFR‐TKI group, 23 out of 33 patients (69%) who were eligible for subsequent treatment received cytotoxic chemotherapy as second‐line treatment. Age, gender, PS, and the number of metastatic sites differed significantly between the cytotoxic chemotherapy and TKI groups (*P* = 0.004, 0.044, 0.001, and 0.030, respectively) (Tables [1](#tca12304-tbl-0001){ref-type="table-wrap"}, [S3](http://onlinelibrary.wiley.com/doi/10.1111/1759-7714.12304/suppinfo)).

![Patient number and analysis flow. CBC, complete blood cell; NLR, neutrophil‐lymphocyte ratio; PFS, progression‐free survival; RR, response rate; TKI, tyrosine kinase inhibitors.](TCA-7-161-g001){#tca12304-fig-0001}

###### 

Patient characteristics

  Variable                       Chemotherapy group (*n* = 165)   TKI group (*n* = 85)   *P* value     Total (*n* = 250)   
  ------------------------------ -------------------------------- ---------------------- ------------- ------------------- ---------------
  Age                            Median (range)                   62 (31--82)            67 (46--85)   0.004               63.6 (31--85)
  Gender                         Male                             73                     26            0.044               99 (39.6%)
  Female                         92                               59                     151 (60.4%)                       
  Disease status                 Recurred disease                 36                     20            0.805               56 (22.4%)
  Initial metastatic disease     129                              65                     194 (77.6%)                       
  Smoking History                Smoker                           53                     21            0.247               74 (29.6%)
  Never‐smoker                   112                              64                     176 (70.4%)                       
  Histologic type                Adenocarcinoma                   150                    79            0.856               229 (91.6%)
  SqCC                           2                                1                      3 (1.2%)                          
  NSCLC, not subtyped            13                               5                      18 (7.2%)                         
  ECOG PS                        0, 1                             155                    59            0.001               214 (85.6%)
  ≥2                             10                               26                     36 (1.4.4%)                       
  EGFR mutation type             Del19                            101                    52            0.988               153 (61.2%)
  L858R                          64                               33                     97 (38.8%)                        
  Number of metastatic sites     1                                42                     29            0.030               71 (28.4%)
  2                              46                               31                     77 (30.8%)                        
  ≥3                             77                               25                     102 (40.8%)                       
  First‐line treatment regimen   Platinum based combination       157                    0             NA                  157 (62.8%)
  Gemcitabine single             7                                0                      7 (2.8%)                          
  Vinorelbine single             1                                0                      1 (0.4%)                          
  TKI                            0                                85                     85 (34.0%)                        
  TKI treatment line             First‐line                       --                     85            NA                  85 (34.0%)
  Second‐line                    152                              --                     152 (60.8%)                       
  Third‐line or further          13                               --                     13 (5.2%)                         

ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; PS, performance status; SqCC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor.

2015 China Lung Oncology Group and Wiley Publishing Asia Pty Ltd

Relationship between the neutrophil‐lymphocyte ratio and response rate {#tca12304-sec-0011}
----------------------------------------------------------------------

Complete blood cell counts and differential count tests were performed for routine pretreatment assessment ([Table S1](http://onlinelibrary.wiley.com/doi/10.1111/1759-7714.12304/suppinfo)). The median time between the CBC count and the first treatment was seven days.

The response rates (RRs) were 29.5% (95% confidence interval \[CI\] 22.9--37.1) in the cytotoxic chemotherapy group and 76.5% (95% CI 66.2--84.4) in the TKI group ([Table S2](http://onlinelibrary.wiley.com/doi/10.1111/1759-7714.12304/suppinfo)). Thirteen patients were not included as a result of loss to follow‐up or early withdrawal from treatment. There was no difference in RR between high and low NLR patients in both the cytotoxic chemotherapy and TKI groups (*P* = 0.595 and 0.173, respectively) (Table [2](#tca12304-tbl-0002){ref-type="table-wrap"}).

###### 

Response rate of first‐line treatment according to (NLR)

  First‐line treatment     Response rate (%)   Total          *P* value        
  ------------------------ ------------------- -------------- ---------------- -------
  Cytotoxic chemotherapy   30/101 (29.7)       16/55 (29.1)   46/156 (29.5)    0.595
  EGFR‐TKI                 46/57 (80.7)        16/24 (66.6)   62/81 (76.5)     0.173
  Total                    76/158 (48.1)       32/79 (40.5)   108/237 (45.6)   

EGFR‐TKI, epidermal growth factor receptor‐tyrosine kinase inhibitor; NLR, neutrophil‐lymphocyte ratio.

2015 China Lung Oncology Group and Wiley Publishing Asia Pty Ltd

Factors associated with progression‐free survival {#tca12304-sec-0012}
-------------------------------------------------

Median PFS was 4.9 months (95% CI 4.266--5.534) in the cytotoxic chemotherapy group and 10.8 months (95% CI 9.167--12.433) in the TKI group (Fig [2](#tca12304-fig-0002){ref-type="fig"}).

![Kaplan--Meier plot for progression‐free survival (PFS) according to neutrophil‐lymphocyte ratio (NLR). A high NLR showed poor PFS in (**a**) the cytotoxic chemotherapy group but (**b**) did not in the TKI group. ![](TCA-7-161-g003.jpg "image"), NLR ≤ 3.0; ![](TCA-7-161-g004.jpg "image"), NLR \> 3.0.](TCA-7-161-g002){#tca12304-fig-0002}

In the cytotoxic chemotherapy group, univariate analysis showed that poor PS, high NLR, and large numbers of metastatic sites were significantly associated with reduced PFS (*P* = 0.004, 0.001, and 0.021, respectively; Table [3](#tca12304-tbl-0003){ref-type="table-wrap"}). However, in the TKI group, a large number of metastatic sites was the only statistically significant association with reduced PFS (*P* = 0.002). Multivariate analysis revealed that the NLR was significantly associated with PFS in the cytotoxic chemotherapy group (*P* \< 0.001, HR 1.882, 95% CI 1.319--2.686), but not in the TKI group (*P* = 0.469, HR 1.239, 95% CI 0.693--2.215; Table [4](#tca12304-tbl-0004){ref-type="table-wrap"}). Age and PS were also significantly associated with PFS in the cytotoxic chemotherapy group (*P* = 0.038 and 0.008, respectively), but the number of metastatic sites at baseline was the only significant association with PFS in the TKI group (*P* = 0.003).

###### 

Univariate analysis of PFS in chemotherapy and TKI treatment groups

  Variable                          Cytotoxic chemotherapy group   TKI treatment group                                                              
  --------------------------------- ------------------------------ --------------------- ------- -------------- ------- ---- ------- -------------- -------
  Age at diagnosis                  ≤65                            97                    0.721   0.530--1.008   0.056   38   0.871   0.523--1.449   0.595
  ≥65                               68                             47                                                                               
  Gender                            M                              73                    0.863   0.631--1.181   0.358   26   0.681   0.402--1.153   0.152
  F                                 92                             59                                                                               
  Pathology                         Adenocarcinoma                 150                   1.096   0.640--1.875   0.738   79   1.317   0.521--3.331   0.560
  SqCC or NSCLC not‐subtyped        15                             6                                                                                
  ECOG PS                           0, 1                           155                   2.573   1.347--4.917   0.004   59   1.469   0.835--2.584   0.182
  ≥2                                10                             26                                                                               
  Smoking                           Smoker                         53                    0.989   0.708--1.384   0.950   21   0.737   0.424--1.282   0.280
  Never‐smoker                      112                            64                                                                               
  Initial disease presentation      Metastatic                     129                   0.724   0.498--1.051   0.089   65   0.581   0.322--1.049   0.072
  Recurred                          36                             20                                                                               
  NLR                               ≤3                             107                   2.037   1.454--2.854   0.001   58   1.363   0.777--2.393   0.280
  \>3                               58                             27                                                                               
  Initial no. of metastatic sites   1,2                            88                    1.457   1.059--2.003   0.021   60   2.406   1.389--4.166   0.002
  ≥3                                77                             25                                                                               

CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; NLR, neutrophil‐lymphocyte ratio; NSCLC, non‐small cell lung cancer; PS, performance status; SqCC, squamous cell carcinoma; TKI, tyrosine kinase inhibitor.

2015 China Lung Oncology Group and Wiley Publishing Asia Pty Ltd

###### 

Multivariate analysis of PFS according to first line treatment

  Variables                                  Chemotherapy   TKI                                                 
  ------------------------------------------ -------------- ------- -------------- --------- --- -------------- -------
  Age                                        ≤ 65 years     1       0.511--0.981   0.038     1   0.533--1.532   0.707
  \>65 years                                 0.708          0.904                                               
  ECOG PS                                    0, 1           1       1.276--4.946   0.008     1   0.662--2.157   0.555
  ≥2                                         2.513          1.195                                               
  No. of metastatic sites before treatment   1, 2           1       0.847--1.678   0.313     1   1.319--4.022   0.003
  ≥3                                         1.192          2.303                                               
  Initial disease presentation               Metastatic     1       0.593--1.278   0.480     1   0.346--1.152   0.134
  Recurred                                   0.871          0.631                                               
  NLR                                        \<3            1       1.319--2.686   \<0.001   1   0.693--2.215   0.469
  ≥3                                         1.882          1.239                                               

CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; NLR, neutrophil‐lymphocyte ratio; PS, performance status; TKI, tyrosine kinase inhibitor.

2015 China Lung Oncology Group and Wiley Publishing Asia Pty Ltd

Discussion {#tca12304-sec-0013}
==========

Our results showed that the NLR had different effects on PFS, according to treatment type. The NLR was a significant prognostic factor in the chemotherapy group, but in EGFR‐mutant NSCLC patients treated with TKIs, PFS was not affected. As for treatment response, the NLR did not affect the RR of cytotoxic chemotherapy or TKI treatment in EGFR‐mutant NSCLC patients.

Cancer‐induced inflammation can elevate the NLR, because both neutrophilia and relative lymphocytopenia occur in various tumors.[12](#tca12304-bib-0012){ref-type="ref"} Several studies have suggested that increased cytokine levels may be responsible for changes in the NLR.[12](#tca12304-bib-0012){ref-type="ref"}, [13](#tca12304-bib-0013){ref-type="ref"}, [14](#tca12304-bib-0014){ref-type="ref"}, [15](#tca12304-bib-0015){ref-type="ref"} For example, increases in interleukin 7 (IL‐7) may increase innate anti‐tumor immunity, whereas increases in IL‐17 or IL‐4 may be associated with tumor‐induced immune suppression.[14](#tca12304-bib-0014){ref-type="ref"}, [15](#tca12304-bib-0015){ref-type="ref"}

Although the underlying causes of changes in the NLR are not well defined, several studies agree that a high NLR (defined as NLR \>3--5) is associated with poor PFS or overall survival (OS) in adjuvant treatment or palliative care settings.[7](#tca12304-bib-0007){ref-type="ref"}, [12](#tca12304-bib-0012){ref-type="ref"} However, it is difficult to compare our findings because most previous studies on the prognostic utility of the NLR in NSCLC did not consider EGFR mutation status or treatment with TKIs. This study evaluated the prognostic utility of the NLR in a relatively homogeneous group of NSCLC patients who all had EGFR mutations, unlike previous studies.[16](#tca12304-bib-0016){ref-type="ref"}, [17](#tca12304-bib-0017){ref-type="ref"}

In patients who received first‐line cytotoxic chemotherapy, the NLR was a significant prognostic factor for PFS, consistent with the results of previous reports.[7](#tca12304-bib-0007){ref-type="ref"}, [18](#tca12304-bib-0018){ref-type="ref"} Although a direct comparison was not possible because of the lack of an EGFR mutation negative study population, this result may suggest that the effect of NLR may have a consistent effect on PFS, regardless of EGFR mutation status, in patients treated with cytotoxic chemotherapy.

There have been few studies investigating the utility of the NLR in NSCLC patients with EGFR mutations treated with TKIs. The post‐hoc analysis of the First‐SIGNAL study showed that the difference between pretreatment and post‐treatment NLRs is a significant prognostic factor, but that pretreatment NLR alone was not significantly associated with either RR or survival.[17](#tca12304-bib-0017){ref-type="ref"} Another study also showed that a pretreatment NLR is not associated with TKI RR.[16](#tca12304-bib-0016){ref-type="ref"}

In our study, the pretreatment NLR was not related to the RR of first‐line treatment nor was it a prognostic factor for PFS in the TKI group.

This suggests that immune status affects the PFS of NSCLC patients treated with TKIs less than those who are treated with cytotoxic chemotherapy as first‐line therapy. Because NSCLC tumors with activating EGFR mutations are dependent on EGFR signal transduction, inhibition of EGFR signaling pathways could counteract immune suppressive effects in the tumor microenvironment.

This study has several limitations. First, because of the retrospective nature of this study, pretreatment CBC counts were not performed at the same time in all patients; however, this might reflect actual clinical settings. Second, post‐treatment blood cell counts were not analyzed. However, the post‐treatment blood cell count can be affected by various situations, such as hidden infection or treatment‐induced hematologic toxicity. Therefore, it may not be a robust factor reflecting survival outcomes. Third, we did not investigate the association between the pretreatment NLR and OS. However, all patients received TKI and more than half of the patients received third‐line or further chemotherapy. Subsequent treatments can affect OS, which makes analysis difficult.

Recently, the results of a programmed death‐1 (PD‐1) or programmed death ligand‐1 (PD‐L1) antibody agent study shed light on immune treatment for lung cancer.[19](#tca12304-bib-0019){ref-type="ref"} The immunologic process involved in cancer development and progress is gaining attention. In terms of TKI treatment, our study suggested that pretreatment immune status may not affect TKI treatment outcome. The survival outcome of a current trial involving a combination of TKIs and an immune checkpoint agent should soon be available.

In conclusion, our results demonstrated that the NLR was a significant prognostic factor in the chemotherapy group, but did not affect either RR or PFS in EGFR‐mutant NSCLC patients treated with TKIs. These findings suggest that pretreatment immune status may not affect the outcome of TKI therapy; however, further research on the role of the NLR in NSCLC patients with EGFR mutations is needed.
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